Efficacy and safety of conbercept, ranibizumab and laser in retinopathy of prematurity: A systematic review and network meta-analysis.
Xuemei Zhu, Dandan Linghu, Xun Deng et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis compared conbercept, ranibizumab, and laser therapy for retinopathy of prematurity across 53 studies involving 8787 eyes. Conbercept ranked highest for cumulative efficacy (SUCRA = 0.815), compared with laser (0.533) and ranibizumab (0.152), although initial treatment responses were comparable. Ranibizumab was associated with more recurrence and retreatment than laser. In exploratory dose analyses, 0.25 mg conbercept combined 82.70% inactivity with 3.84% adverse events; the 0.3 mg dose had higher efficacy but limited safety data.
Key findings
- Conbercept ranked highest for cumulative efficacy: SUCRA = 0.815, versus 0.533 for laser and 0.152 for ranibizumab.
- Compared with laser, ranibizumab had higher recurrence (RR = 3.62, 95%CI:1.31-11.64) and retreatment (RR = 2.31, 95%CI:1.18-5.55).
- Conbercept ocular adverse-event rates were 3.85%, versus 9.82% with laser and 5.03% with ranibizumab.
- The 0.25 mg conbercept dose had 82.70% inactivity and 3.84% adverse events; 0.3 mg achieved 90.7% efficacy, with limited safety data.
Why it matters
The analysis compares efficacy, recurrence, retreatment, and safety across commonly evaluated ROP treatments, outcomes that inform assessment of treatment trade-offs. Its findings suggest that rankings differ by outcome: conbercept ranked highest for cumulative efficacy, while laser ranked best for preventing recurrence. Dose-specific results may also help frame questions about balancing response and safety, but require cautious interpretation.
What to keep in mind
The evidence combines randomised trials, retrospective studies, and single-arm studies; the abstract does not report study-level certainty or comparative safety data for the 0.3 mg dose.